Free Trial

This company recently went public with an IPO on Friday, October 30th 2026. They issued 10,555,555 shares at $16.00 per share. We will continue to update data for BBTX as it becomes available.

Bambusa Therapeutics (BBTX) 10K Form and Latest SEC Filings 2026

$16.00 +1.01 (+6.74%)
As of 04:00 PM Eastern

Latest Bambusa Therapeutics SEC Filings & Recent Activity

Bambusa Therapeutics (NASDAQ:BBTX) has submitted 18+ documents to the U.S. Securities and Exchange Commission (SEC) since 2025. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form 424B4 submitted on October 30, 2026.

Filing Date
0 Results
DateFilerForm TypeView
10/30/2026 3:02 PM
Bambusa Therapeutics (2044950) Filer
Form 424B4
10/29/2026 11:15 PM
Bambusa Therapeutics (2044950) Filer
Form EFFECT
10/29/2026 4:19 PM
Bambusa Therapeutics (2044950) Filer
Form S-1MEF
10/29/2026 3:30 PM
Bambusa Therapeutics (2044950) Issuer
DiRocco Derek (1792061) Reporting
Form 3
Initial statement of beneficial ownership of securities  
10/29/2026 3:31 PM
Bambusa Therapeutics (2044950) Issuer
Liang Howard (1663427) Reporting
Form 3
Initial statement of beneficial ownership of securities  
10/29/2026 3:33 PM
Bambusa Therapeutics (2044950) Issuer
Jeggle Helmut Wolfgang (1982614) Reporting
Form 3
Initial statement of beneficial ownership of securities  
10/29/2026 3:33 PM
Bambusa Therapeutics (2044950) Issuer
Kolchinsky Peter (1384859) Reporting
RA Capital Healthcare Fund LP (1315082) Reporting
RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting
RA Capital Nexus Fund III, L.P. (1883840) Reporting
Shah Rajeev M. (1619841) Reporting
Form 3
Initial statement of beneficial ownership of securities  
10/29/2026 3:34 PM
Bambusa Therapeutics (2044950) Issuer
Salvia Investment GmbH (2162499) Reporting
Form 3
Initial statement of beneficial ownership of securities  
10/29/2026 3:26 PM
Bambusa Therapeutics (2044950) Issuer
MiNeng, Inc. (2161367) Reporting
Xu Shanshan (2160743) Reporting
Form 3
Initial statement of beneficial ownership of securities  
10/29/2026 3:27 PM
Bambusa Therapeutics (2044950) Issuer
Ho Minh Quoc Thang (2159278) Reporting
Form 3
Initial statement of beneficial ownership of securities  
10/29/2026 3:28 PM
Bambusa Therapeutics (2044950) Issuer
Lieber Jonathan I (1350090) Reporting
Form 3
Initial statement of beneficial ownership of securities  
10/29/2026 11:59 AM
Bambusa Therapeutics (2044950) Filer
Form CERT
10/27/2026 2:33 PM
Bambusa Therapeutics (2044950) Filer
Form 8-A12B
10/26/2026 5:04 AM
Bambusa Therapeutics (2044950) Filer
Form S-1/A
10/09/2026 4:08 PM
Bambusa Therapeutics (2044950) Filer
Form S-1
Registration statement under Securities Act of 1933  
(Data available from 1/1/2016 forward)

Bambusa Therapeutics SEC Filings - Frequently Asked Questions

Bambusa Therapeutics (BBTX) has submitted 18+ filings to the SEC since 2025. You can browse the complete history or filter by form type using the tools above.

The most recent filing was a Form 424B4 submitted on October 30, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


SEC filings for NASDAQ:BBTX are sourced directly from the U.S. Securities and Exchange Commission (SEC), with the most recent filing dated 10/30/2026. New filings are added as they're published.
From Our Partners